Literature DB >> 20434789

Suppression of hydroxyurea-induced centrosome amplification by NORE1A and down-regulation of NORE1A mRNA expression in non-small cell lung carcinoma.

Kazuya Shinmura1, Hong Tao, Kiyoko Nagura, Masanori Goto, Shun Matsuura, Takahiro Mochizuki, Kazuya Suzuki, Masayuki Tanahashi, Hiroshi Niwa, Hiroshi Ogawa, Haruhiko Sugimura.   

Abstract

The candidate tumor suppressor NORE1A is a nucleocytoplasmic shuttling protein, and although a fraction of the NORE1A in cells is localized to their centrosomes, the role of centrosomal NORE1A has not been elucidated. In this study we investigated the role of NORE1A in the numerical integrity of centrosomes and chromosome stability in lung cancer cells. Exposure of p53-deficient H1299 lung cancer cell line to hydroxyurea (HU) resulted in abnormal centrosome amplification (to 3 or more centrosomes per cell) as determined by immunofluorescence analysis with anti-γ-tubulin antibody, and forced expression of wild-type NORE1A partially suppressed the centrosome amplification. The nuclear export signal (NES) mutant (L377A/L384A) of NORE1A did not localize to centrosomes and did not suppress the centrosome amplification induced by HU. Fluorescence in situ hybridization analyses with probes specific for chromosomes 2 and 16 showed that wild-type NORE1A, but not NES-mutant NORE1A, suppressed chromosome instability in HU-exposed H1299 cells that was likely to have resulted from centrosome amplification. We next examined the status of NORE1A mRNA expression in non-small cell lung carcinoma (NSCLC) and detected down-regulation of NORE1A mRNA expression in 25 (49%) of 51 primary NSCLCs by quantitative real-time-polymerase chain reaction analysis. These results suggest that NORE1A has activity that suppresses the centrosome amplification induced by HU and that NORE1A mRNA down-regulation is one of the common gene abnormalities in NSCLCs, both of which imply a key preventive role of NORE1A against the carcinogenesis of NSCLC.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20434789     DOI: 10.1016/j.lungcan.2010.04.006

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  7 in total

1.  NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis.

Authors:  Li-Li Liu; Mei-Fang Zhang; Ying-Hua Pan; Jing-Ping Yun; Chris Zhiyi Zhang
Journal:  Tumour Biol       Date:  2014-02-25

2.  PLK4 overexpression and its effect on centrosome regulation and chromosome stability in human gastric cancer.

Authors:  Kazuya Shinmura; Nobuya Kurabe; Masanori Goto; Hidetaka Yamada; Hiroko Natsume; Hiroyuki Konno; Haruhiko Sugimura
Journal:  Mol Biol Rep       Date:  2014-07-01       Impact factor: 2.316

3.  RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma.

Authors:  Wei Guo; Cong Wang; Yanli Guo; Supeng Shen; Xin Guo; Gang Kuang; Zhiming Dong
Journal:  Clin Exp Metastasis       Date:  2015-01-13       Impact factor: 5.150

4.  Ras regulates SCF(β-TrCP) protein activity and specificity via its effector protein NORE1A.

Authors:  M Lee Schmidt; Howard Donninger; Geoffrey J Clark
Journal:  J Biol Chem       Date:  2014-09-12       Impact factor: 5.157

5.  Ras Regulates Rb via NORE1A.

Authors:  Thibaut Barnoud; Howard Donninger; Geoffrey J Clark
Journal:  J Biol Chem       Date:  2015-12-16       Impact factor: 5.157

Review 6.  A clinical overview of centrosome amplification in human cancers.

Authors:  Jason Yongsheng Chan
Journal:  Int J Biol Sci       Date:  2011-10-16       Impact factor: 6.580

Review 7.  Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies.

Authors:  Karuna Mittal; Jaspreet Kaur; Meghan Jaczko; Guanhao Wei; Michael S Toss; Emad A Rakha; Emiel Adrianus Maria Janssen; Håvard Søiland; Omer Kucuk; Michelle Dian Reid; Meenakshi V Gupta; Ritu Aneja
Journal:  Cancer Metastasis Rev       Date:  2020-10-26       Impact factor: 9.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.